NASDAQ: HYFTMindwalk Holdings Corp Stock
$1.94-0.05 (-2.51%)
Updated Sep 5, 2025
HYFT Price
$1.94
Fair Value Price
N/A
Market Cap
$89.54M
52 Week Low
$0.27
52 Week High
$3.25
P/E
-2.92x
P/B
5.19x
P/S
0.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$17.90M
Earnings
-$21.91M
Gross Margin
55.3%
Operating Margin
-138.6%
Profit Margin
-123.3%
Debt to Equity
0.88
Operating Cash Flow
-$5M
Beta
0.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HYFT Overview
ImmunoPrecise Antibodies Limited focues on discovering therapeutic antibodies. It aims for species-agnostic advancements such as B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, and Abthena bispecific program. The company has research collaboration agreements with Pierre Fabre S.A and Elektrofi Inc. ImmunoPrecise Antibodies was incorporated in 1983 and is headquartered in Victoria, British Columbia, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HYFT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HYFT
Ranked#38 of 482
Ranked#38 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.95 | A | |
| $41.34 | A | |
| $12.40 | A |
Be the first to know about important HYFT news, forecast changes, insider trades & much more!
HYFT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HYFT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HYFT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HYFT is poor value based on its book value relative to its share price (5.19x), compared to the US Biotechnology industry average (4.72x)
P/B vs Industry Valuation
HYFT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HYFT due diligence checks available for Premium users.
Valuation
HYFT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.92x
Industry
-122.34x
Market
35.5x
HYFT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.19x
Industry
4.72x
HYFT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HYFT's financial health
Profit margin
Revenue
$5.1M
Net Income
-$1.6M
Profit Margin
-31%
HYFT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HYFT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$32.2M
Liabilities
$15.1M
Debt to equity
0.88
HYFT's short-term assets ($13.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HYFT's short-term assets ($13.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HYFT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HYFT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$826.1k
Investing
-$260.1k
Financing
-$302.9k
HYFT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HYFT vs Biotech Stocks
Mindwalk Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.